News

Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients in an Oral Presentation at the 63rd European Renal Association Congress

Schlieren / Zurich, Switzerland, 5 June, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today shared additional data analysis from its Phase II study of potravitug at the European Renal Association (ERA) Congress. The oral presentation detailed findings...

read more

LimmaTech Biologics to be Acquired by Lilly for Nextgeneration Vaccines Against Common Bacterial Infections

Schlieren (Zurich), May 26, 2026 –LimmaTech Biologics AG, a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced entry into a definitive agreement to be acquired by Lilly. LimmaTech is developing vaccines against bacterial pathogens for which rising antimicrobial resistance is steadily closing therapeutic options, including...

read more

InSphero Accelerates Global Growth and US Expansion with Acquisition of PhenoVista Biosciences

Schlieren, Switzerland - May 20, 2026 Strategic acquisition strengthens InSphero’s presence in the United States and expands advanced imaging and phenotypic analysis capabilities for drug discovery and safety testing InSphero, the global leader in advanced 3D in vitromodels and services for drug safety and efficacy testing, today announced the acquisition of California-based...

read more